- Home
- ARCB vs AKRO Comparison
ARCB vs AKRO Comparison
Compare ARCB & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCB
- AKRO
- Stock Information
- Founded
- ARCB 1923
- AKRO 2017
- Country
- ARCB United States
- AKRO United States
- Employees
- ARCB N/A
- AKRO N/A
- Industry
- ARCB Trucking Freight/Courier Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ARCB Industrials
- AKRO Health Care
- Exchange
- ARCB Nasdaq
- AKRO Nasdaq
- Market Cap
- ARCB 2.6B
- AKRO 2.2B
- IPO Year
- ARCB N/A
- AKRO 2019
- Fundamental
- Price
- ARCB $106.69
- AKRO $29.68
- Analyst Decision
- ARCB Buy
- AKRO Strong Buy
- Analyst Count
- ARCB 14
- AKRO 8
- Target Price
- ARCB $130.69
- AKRO $46.83
- AVG Volume (30 Days)
- ARCB 221.0K
- AKRO 535.2K
- Earning Date
- ARCB 02-04-2025
- AKRO 11-08-2024
- Dividend Yield
- ARCB 0.45%
- AKRO N/A
- EPS Growth
- ARCB 8.96
- AKRO N/A
- EPS
- ARCB 8.07
- AKRO N/A
- Revenue
- ARCB $4,266,908,999.00
- AKRO N/A
- Revenue This Year
- ARCB N/A
- AKRO N/A
- Revenue Next Year
- ARCB $4.21
- AKRO N/A
- P/E Ratio
- ARCB $13.14
- AKRO N/A
- Revenue Growth
- ARCB N/A
- AKRO N/A
- 52 Week Low
- ARCB $94.77
- AKRO $15.32
- 52 Week High
- ARCB $153.60
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- ARCB 46.15
- AKRO 46.87
- Support Level
- ARCB $105.74
- AKRO $28.45
- Resistance Level
- ARCB $113.74
- AKRO $31.41
- Average True Range (ATR)
- ARCB 3.09
- AKRO 1.29
- MACD
- ARCB -0.53
- AKRO -0.15
- Stochastic Oscillator
- ARCB 27.87
- AKRO 37.64
About ARCB ArcBest Corporation
ArcBest Corp is engaged in logistics operations. The company operates in two operating segments, The Asset-Based segment includes the results of operations of ABF Freight System, Inc. and certain other subsidiaries. The segment operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed LTL services. The services including freight transportation related to managed transportation solutions and other services. The Asset-Light segment includes the results of operations of the Company's service offerings in truckload, ground expedite, dedicated, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.